Company intelligence / Profile preview

PanTher Therapeutics

Watertown, Massachusetts, United Statespanthertx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

PanTher Therapeutics has developed the Sagittari™ platform for localized, sustained release of oncology drugs directly at the tumor site. Their lead candidate, PTM‑101 for pancreatic cancer using paclitaxel implants, has completed a small Phase I study showing local response and excellent safety with no serious adverse events or systemic toxicity. The company reports over a hundredfold increase in drug concentration at the tumor compared to systemic administration and minimal side effects. Additional programs are advancing preclinically.

Therapeutic areas: Oncology
Modalities: Localized drug delivery (polymer-based implantable therapeutics)Small molecules (e.g., paclitaxel)
Industry: Biotech

Drug pipeline

2 assets

PTM-101

1 more asset in the full pipeline.

Beyond the preview

Go deeper on PanTher Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanTher Therapeutics.